The first time I prescribed semaglutide, in 2019, the patient cried. Not because the medicine had worked yet — it hadn't; she hadn't even taken her first dose — but because for the first time in twenty years a clinician had told her the appetite she'd been fighting was a hormone, not a moral failing.
That moment is most of why I do this work. It is also the moment I keep in mind every time someone — a friend, a podcast host, a stranger at a wedding — calls GLP-1 medication "the easy way out." Because the line is wrong, but it isn't lazy. The people saying it have done some version of the work it implies you're skipping. They want to know what was the point.
I want to answer them carefully. Here's what I'd say.
What the drug actually is
GLP-1 — glucagon-like peptide 1 — is a hormone your gut releases after you eat. It nudges insulin, slows gastric emptying, and signals satiety to your brain. In some people, that signal is loud and steady. In others, for reasons that include genetics, sleep debt, chronic dieting, and decades of insulin resistance, the signal is whispered, intermittent, or routinely overridden. Semaglutide, tirzepatide, and the rest of the GLP-1 / GIP family are not creating an unfamiliar physiology. They are turning the volume back up on a signal you were supposed to have all along.
That is not a shortcut. That is a correction.
What "the work" still is
Here's the part the shortcut conversation tends to skip. Once the appetite signal is restored, you still have to live in it. The dose makes the next twelve months possible. The next twelve months make the next ten years.
What members tell us, after the second or third month — once the novelty fades and the scale is moving in the boring kind of way — is that the medicine bought them a quieter mind. Food noise turns down. Negotiations with the pantry stop being negotiations. And in that quiet, the work shows up.
- Protein. If your appetite is reduced by a third, you are at real risk of under-eating protein. We coach members toward roughly a gram per pound of goal body weight, spread across three or four meals. Lean mass is the dial that controls what you look like, what you can lift, and how you metabolize the rest of your life.
- Walking. Not the cardio of social media. Just walking — twenty, thirty, sixty minutes a day, distributed however it fits. It blunts the post-meal glucose spike, supports lymphatic drainage, and gives the medication something to work with.
- Sleep. Sleep is hormonal. People who chronically sleep less than seven hours run higher fasting insulin and higher cortisol, and they eat more the next day. (We have a longer note on this — sleep is the quiet protocol.)
- Strength. Two short resistance sessions per week, even with light loads, will preserve the lean mass you'd otherwise lose alongside the fat. This matters more at forty than thirty, and more at sixty than forty.
None of that is glamorous. None of it sells T-shirts. All of it is the work the medication makes possible, not the work the medication replaces.
The boring middle
There is a stretch of GLP-1 treatment, somewhere between week eight and month six, that we privately call "the boring middle." The dramatic phase is over. The before-and-after photos haven't accumulated yet. You feel mostly fine, your jeans fit differently, and the question that surfaces — quietly, on a Sunday afternoon — is "am I supposed to be doing more?"
The honest answer is no. You're supposed to be doing this, slowly, for a long time, with a clinician who knows you.
The boring middle is the entire point. It is the period in which a body learns that this is just how it eats now. It is the period in which a person quietly forgets they used to think about food every twenty minutes. It is, on a long enough timeline, where the change becomes permanent — not because the drug did it but because the conditions for change held long enough for the body and the calendar to agree.
So is it a shortcut?
By the standard the question implies — that there's a "right" amount of suffering, and the medication helps you skip it — no. There is no virtue in suffering with a hormone problem, any more than there is virtue in suffering with hypothyroidism or refractory depression. The pharmaceutical isn't subverting a moral economy; it's subverting an inefficient one.
By the standard the question is afraid of — that this is something you take instead of doing the work — also no. The work is still here. The work was always going to be here. What changed is the floor you do it from.
That, in the end, is the version of this I tell people. The drug isn't the shortcut. The shortcut is realizing the work was always supposed to be sustainable.
If you've been quietly considering it, the eligibility review on our platform takes about twelve minutes, costs nothing, and gets you an honest answer from a clinician. If we're not the right fit, we'll tell you. If we are, we'll keep at it together, slowly, for as long as you want to.
